Bengaluru-based startup Cardiotrack, a brand of Uber Diagnostics, has received $2 million in Pre series-A funding from a slew of investors, led by seasoned angel investor Girish Narasimhan. Previously, the firm had received an angel investment of $1.6 million from a cohort of UHNIs.

Cardiotrack delivers the most comprehensive at-home pathology and radiology screening services, in 300+ locations through its strong pan-India network of diagnostic centres, technicians and phlebotomists equipped with its technology, to provide the best in the industry geographical coverage and turn-around time to its health and life insurance customers.

A standout feature of Cardiotrack's unique screening technologies is the equivalent of a treadmill test, being conducted in the comfort of one's home along with video-based recorded medical examinations.

Commenting on the funding, Avin Agarwal, Founder & CEO, Cardiotrack, said, “We are thrilled to have secured this investment as we continue to innovate and expand our reach in our mission to drive positive change in the healthcare industry. Our revolutionary approach to healthcare screening not only enhances convenience for consumers but also enables health and life insurance providers to offer fast, comprehensive and personalised services, besides increased operational efficiency and improving our healthcare data analytics capabilities for faster and more accurate insurance underwriting. The investment further validates the venture’s direction and the immense value it brings in improving the healthcare experience for both providers and consumers." 

The pre-series A funding is led by Girish Narasimhan, Managing Director & Principal, Corporate Finance Associates Worldwide Inc. along with seasoned professional and co-investor Y S Shashidhar, Advisor, Dubai Holdings LLC  (& former Partner & Managing Director at Frost & Sullivan for Middle East, Africa and South Asia Region) joining in.